544449

Anthem Biosciences Limited informed about its participation in upcoming analyst/institutional investor meetings. The company will attend the Nomura Investment Forum Asia 2026 in Singapore on June 2-3, 2026, and the Citi India Conference 2026 in Mumbai on June 4-5, 2026. Both events will feature one-on-one and group meetings. No unpublished price-sensitive information will be discussed during these interactions.

Management highlighted a strong FY26 and record Q4, with aspirations for 20%+ long-term growth and maintaining high EBITDA margins (expected to continue at current levels, around 38-40% or higher). The company will invest approximately ₹1,200 crores in Capex over FY27-FY28 (₹700 Cr in FY27), primarily for Unit 4 expansion to double custom synthesis and increase fermentation capacity by 50%. Key growth drivers include investments in technology, expanding big pharma relationships, and a robust pipeline with 10 Phase 3 programs. Destocking is mostly complete, with positive future impact expected. Biotech funding is recovering, and recently commercialized molecules are contributing significantly.

Anthem Biosciences Limited announced the availability of the audio recording of the Earnings Call held on May 20, 2026, for the quarter and year ended March 31, 2026. The recording, which covers the Audited Standalone and Consolidated Financial Results, is accessible on the company's website.

Consolidated Revenue from Operations was ₹6,109 Mn vs ₹4,832 Mn (▲26.4% YoY), EBITDA was ₹3,184 Mn vs ₹2,092 Mn (▲52.2% YoY), PAT was ₹1,898 Mn vs ₹826 Mn (▲129.8% YoY). EBITDA Margin expanded to 48.1% from 43.29% (▲481bps). Management noted strong performance with the highest revenue quarter and expanded profitability margins.

Standalone Revenue ₹582.50 Cr vs ₹478.98 Cr (▲21.62% YoY), EBITDA ₹267.96 Cr vs ₹198.11 Cr (▲35.26% YoY), PAT ₹211.66 Cr vs ₹122.56 Cr (▲72.70% YoY). EBITDA Margin 46.00% vs 41.36% (▲464 bps). The board also recommended a final dividend of INR 2.00 per equity share for the financial year ended March 31, 2026.

Anthem Biosciences disclosed Key Performance Indicators. For FY2026, total revenue grew 15.17% YoY to ₹21,243.33 million, EBITDA rose 31.21% to ₹8,971.69 million, and PAT increased 31.14% to ₹5,917.92 million. For the six months ended September 30, 2024, total revenue saw a significant 46.72% YoY increase to ₹8,635.50 million, EBITDA grew 47.86% to ₹3,275.04 million, and PAT surged 55.51% to ₹2,443.60 million, indicating strong recent performance.

Standalone Revenue ₹582.50 Cr vs ₹479.00 Cr (▲21.61% YoY), EBITDA ₹267.96 Cr vs ₹198.11 Cr (▲35.26% YoY), PAT ₹211.66 Cr vs ₹122.56 Cr (▲72.70% YoY). EBITDA Margin 46.00% vs 41.36% (▲464bps). The Board also recommended a final dividend of INR 2.00 per equity share for the financial year ended March 31, 2026.

Anthem Biosciences Limited's Audited Standalone Annual Results for FY26 show strong performance: Revenue from operations ₹2,089.31 Cr vs ₹1,840.65 Cr (▲13.51% YoY), EBITDA ₹827.11 Cr vs ₹689.01 Cr (▲20.04% YoY), PAT ₹670.56 Cr vs ₹506.19 Cr (▲32.48% YoY). EBITDA Margin expanded to 39.59% vs 37.43% (▲216 bps). The Board also recommended a final dividend of INR 2.00 per equity share and approved the re-appointment of internal and whole-time directors.

For the quarter ended March 31, 2026, Standalone Revenue ₹582.50 Cr vs ₹478.98 Cr (▲21.61% YoY), EBITDA ₹328.59 Cr vs ₹235.93 Cr (▲39.27% YoY), PAT ₹211.67 Cr vs ₹122.56 Cr (▲72.70% YoY). EBITDA Margin 56.41% vs 49.25% (▲716bps). The Board also recommended a final dividend of INR 2.00 per equity share for the financial year ended March 31, 2026.

Consolidated Revenue from Operations for Q4FY26 was ₹6,109 Mn vs ₹4,832 Mn (▲26.4% YoY). EBITDA was ₹3,184 Mn vs ₹2,092 Mn (▲52.2% YoY). PAT was ₹1,898 Mn vs ₹826 Mn (▲129.8% YoY). EBITDA Margin expanded to 48.1% from 43.3% (▲480bps) YoY. Management noted this was their highest revenue quarter ever and highlighted strong profitability and healthy financial position.

Consolidated Revenue ₹2,124.33Cr vs ₹1,844.55Cr (▲15.17% YoY), EBITDA ₹809.42Cr vs ₹670.84Cr (▲20.66% YoY), PAT ₹591.79Cr vs ₹451.26Cr (▲31.14% YoY). EBITDA Margin 38.10% vs 36.37% (▲173bps). The Board also recommended a final dividend of INR 2.00 per equity share for FY26 and approved the re-appointment of internal auditors and directors.

Anthem Biosciences Limited reported strong consolidated financial results for the quarter ended March 31, 2026. Consolidated Revenue stood at ₹610.94Cr compared to ₹483.20Cr (▲26.43% YoY), EBITDA at ₹319.41Cr compared to ₹209.25Cr (▲52.64% YoY), and PAT at ₹189.76Cr compared to ₹82.62Cr (▲129.67% YoY). EBITDA Margin expanded significantly to 52.28% from 43.31% (▲897bps). The Board also recommended a final dividend of INR 2.00 per equity share.